Brief Title: A Study of a Side Effects and Resource Navigation Program for People With Cancer

PRIMARY OUTCOMES

Primary Outcome 1 - Measure: Immune Checkpoint Inhibitors/ICI continuation

Primary Outcome 1 - Timeframe: 6 months

CONDITION

• Kidney Cancer
• Bladder Cancer
• Breast Cancer
• Lung Cancer

ELIGIBILITY

Inclusion Criteria:
* Documentation of Disease
o Patient must have pathologically confirmed kidney, bladder, breast, or lung cancer (per EMR)

- * Prior Treatment
o Within three weeks (+/- 3 weeks) of starting PD-1 or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR)

- * Age ≥ 18 (per EMR)

- * Not Pregnant and Not Nursing (per self-report)

- * At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report)

- * Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report)

- * Can speak English or Spanish (per self-report)

- * Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team)

- * Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team)

Gender: All

Minimum Age: 18 Years

Maximum Age: N/A

Healthy Volunteers: No

OFFICIAL INFORMATION

Name: Francesca Gany, MD, MS

Role: Principal Investigator

Affiliation: Memorial Sloan Kettering Cancer Center

Overall Contact

Name: Francesca Gany, MD, MS, Neil Shah, MBBS

Phone: 646-888-8054, 646-888-4239

Email: [email protected], [email protected]

LOCATION